"Daunorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
| Descriptor ID |
D003630
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200 D04.615.562.050.200 D09.408.051.059.200
|
| Concept/Terms |
Daunorubicin- Daunorubicin
- Daunomycin
- Rubomycin
- Dauno-Rubidomycine
- Dauno Rubidomycine
- Rubidomycin
|
Below are MeSH descriptors whose meaning is more general than "Daunorubicin".
Below are MeSH descriptors whose meaning is more specific than "Daunorubicin".
This graph shows the total number of publications written about "Daunorubicin" by people in this website by year, and whether "Daunorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 1 | 4 | 5 |
| 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Daunorubicin" by people in Profiles.
-
Prediction of potential therapeutic drugs against SARS-CoV-2 by using Connectivity Map based on transcriptome data. Eur Rev Med Pharmacol Sci. 2021 04; 25(7):3122-3131.
-
COVID-19 reinfection in two children with cancer. Pediatr Hematol Oncol. 2021 05; 38(4):403-405.
-
Successful management of SARS-CoV-2 acute respiratory distress syndrome and newly diagnosed acute lymphoblastic leukemia. Blood Adv. 2020 09 22; 4(18):4358-4361.
-
Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic. Br J Haematol. 2020 08; 190(4):e208-e210.
-
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. J Clin Oncol. 2019 09 01; 37(25):2246-2256.
-
Nuclear Lipid Microdomains Regulate Daunorubicin Resistance in Hepatoma Cells. Int J Mol Sci. 2018 Nov 01; 19(11).
-
Safety and feasibility of a low frame rate protocol for percutaneous coronary intervention to chronic total occlusions: preliminary experience. EuroIntervention. 2018 Aug 03; 14(5):e538-e545.
-
The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols. Br J Haematol. 2018 09; 182(5):705-711.
-
Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood. 2018 07 26; 132(4):405-412.
-
Cutaneous herald: leukaemia cutis as presenting manifestation of relapse in acute promyelocytic leukaemia. BMJ Case Rep. 2018 May 02; 2018.